Review: taking Vyvanse and Suboxone together


Summary

Drug interactions are reported among people who take Vyvanse and Suboxone together. This review analyzes the effectiveness and drug interactions between Vyvanse and Suboxone. It is created by eHealthMe based on reports of 96 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Vyvanse

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Vyvanse 12,820 users)

Suboxone

Suboxone has active ingredients of buprenorphine hydrochloride; naloxone hydrochloride. It is often used in drug dependence. (latest outcomes from Suboxone 15,626 users)

On Sep, 16, 2016

96 people who take Vyvanse, Suboxone are studied.


Number of reports submitted per year:

Vyvanse and Suboxone drug interactions.

Drug effectiveness over time:

Vyvanse:
  • < 1 month: 37.0% - (3 of 8 people)
  • 1 - 6 months: 46.0% - (6 of 13 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 33.0% - (1 of 3 people)
  • 2 - 5 years: 100.0% - (4 of 4 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 1 people)
Suboxone:
  • < 1 month: 40.0% - (2 of 5 people)
  • 1 - 6 months: 100.0% - (5 of 5 people)
  • 6 - 12 months: 100.0% - (8 of 8 people)
  • 1 - 2 years: 50.0% - (2 of 4 people)
  • 2 - 5 years: 100.0% - (6 of 6 people)
  • 5 - 10 years: 100.0% - (2 of 2 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 100.0% - (1 of 1 people)

Drug effectiveness by gender:

Vyvanse:
  • female: 52.0% - (11 of 21 people)
  • male: 50.0% - (5 of 10 people)
Suboxone:
  • female: 86.0% - (19 of 22 people)
  • male: 77.0% - (7 of 9 people)

Drug effectiveness by age:

Vyvanse:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 45.0% - (5 of 11 people)
  • 30-39: 46.0% - (7 of 15 people)
  • 40-49: 75.0% - (3 of 4 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 0 people)
Suboxone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 83.0% - (10 of 12 people)
  • 30-39: 93.0% - (14 of 15 people)
  • 40-49: 33.0% - (1 of 3 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • adverse drug reaction
  • hypertension
  • nausea
  • bronchitis
  • chills
  • drug ineffective
  • fatigue
  • hot flush
  • hyperhidrosis
  • hypoacusis
1 - 6 months:
  • headache
  • aches and pains in bones
  • belching
  • dizziness
  • drug withdrawal syndrome neonatal
  • drug ineffective
  • euphoric mood
  • fatigue
  • fever
  • foetal exposure during pregnancy
6 - 12 months:
  • appetite decreased
  • constipation
  • sweating - excessive
  • breech presentation
  • confusion
  • drug withdrawal syndrome neonatal
  • fatigue - chronic
  • foetal distress syndrome
  • foetal exposure during pregnancy
  • hair texture abnormal
1 - 2 years:
  • chills
  • euphoric mood
  • gastrointestinal pain
  • gastrooesophageal reflux disease
  • hiatus hernia
  • impaired gastric emptying
  • therapeutic response unexpected
  • weight increased
  • abnormal sleep-related event
  • abortion spontaneous
2 - 5 years:
  • exhaustion, fatigue, lethargy, tiredness, weariness
  • headache
  • aches and pains in bones
  • belching
  • appetite decreased
  • constipation
  • fever
  • sweating - excessive
  • abdominal pain upper
  • diarrhoea
5 - 10 years:
  • gastrooesophageal reflux disease
  • hiatus hernia
  • impaired gastric emptying
  • abnormal sleep-related event
  • chest pain
  • decreased eye contact
  • hypersomnia
  • impulsive behaviour
  • inappropriate affect
  • obsessive-compulsive disorder
not specified:
  • somnolence
  • constipation
  • dizziness
  • drug ineffective
  • feeling abnormal
  • nausea
  • weight increased
  • irritability
  • asthenia
  • chills

Most common drug interactions by gender *:

female:
  • feeling abnormal
  • hot flush
  • nausea
  • obsessive-compulsive disorder
  • weight increased
  • drug diversion
  • dyspnoea
  • bronchitis
  • chills
  • depression
male:
  • drug withdrawal syndrome neonatal
  • foetal exposure during pregnancy
  • somnolence
  • fatigue
  • constipation
  • drug ineffective
  • nausea
  • aggression
  • dizziness
  • drug intolerance

Most common drug interactions by age *:

0-1:
  • drug withdrawal syndrome neonatal
  • foetal exposure during pregnancy
  • jaundice neonatal
  • premature baby
  • maternal drugs affecting foetus
  • breech presentation
  • foetal distress syndrome
20-29:
  • aggression
  • drug intolerance
  • impaired driving ability
  • intentional overdose
  • mania
  • constipation
  • gastrointestinal pain
  • gastrooesophageal reflux disease
  • hiatus hernia
  • impaired gastric emptying
30-39:
  • hot flush
  • nausea
  • bronchitis
  • chills
  • hyperhidrosis
  • hypoacusis
  • neuralgia
  • pain
  • polychondritis
  • therapeutic response unexpected
40-49:
  • depression
  • drug effect decreased
  • drug effect increased
  • insomnia
  • irritability
  • lethargy
  • logorrhoea
  • obsessive-compulsive disorder
  • activities of daily living impaired
  • anxiety
50-59:
  • asthenia
  • asthma
  • constipation
  • disturbance in attention
  • dyspnoea
  • feeling abnormal
  • hallucination
  • oedema peripheral
  • periorbital oedema
  • somnolence
60+:
  • abdominal pain
  • constipation
  • myocardial infarction
  • urinary retention
  • hyperlipidaemia
  • hypertensive heart disease
  • nausea
  • unresponsive to stimuli

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Vyvanse and Suboxone?

Can you answer these questions?

More questions for: Vyvanse, Suboxone

You may be interested in these reviews

More reviews for: Vyvanse, Suboxone

On eHealthMe, Vyvanse (lisdexamfetamine dimesylate) is often used to treat attention deficit hyperactivity disorder. Suboxone (buprenorphine hydrochloride; naloxone hydrochloride) is often used to treat drug dependence. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.